1.Study on the clinical pathology of gastrointestinal stromal tumors
Cancer Research and Clinic 2006;0(08):-
The content of gastrointestinal stromal tumors had changed many times since the appearance of this idea. Along with the progress of molecular and biological study in recent years, it was a kind of tumor with specific clinical, pathological and molecular genetic characteristics, and was different from other specific tumors originated from the smooth muscle or nerves. Along with the success of targeted therapy of GIST, the disease was paid more attention. Therefore, a review of the clinical pathological study of GIST was needed.
2.Molecular and biologic study of gastrointestinal stromal tumors
Cancer Research and Clinic 2006;0(08):-
Gastrointestinal stromal tumors is a new kind of tumor known recently, especially the important progress in the molecular and biologic study of GIST were used quickly in the clinical diagnosis and treatment, and made a close combination of basic research and clinical applications. The study and application of target therapy of new molecules on the mechanism of molecular genetics of GIST was another successful example. Therefore, GIST was paid extensive attention by the scholars. The progress on the molecular and biological study was summarized.
6.Expression of HER4 in esophageal carcinoma tissues and its clinical significance
Weigang GUO ; Di GE ; Xuguang PANG ; Dong XIE ; Yingyong HOU
Tumor 2009;(7):673-676
Objective:To investigate the expression of human epidermal growth factor receptor 4 (HER4) and metastasis-related protein (MMP-9) in human esophageal carcinoma tissues, and their relationship with clinicopathological features of the disease. Methods:Immunohistochemical Envision technique was applied to detect the expressions of HER4 and MMP-9 in 45 specimens of esophageal carcinoma tissues, paracancerous tissues and normal tissues. Statistical method was used to analyze the association of the positivity of HER4 with clinical pathological index and MMP-9 expression.Results:The positive rates of HER4 expression were 73.3%, 33.3%, and 2.2% in 45 specimens of esophageal carcinoma tissues, paracancerous tissues, and normal tissues, respectively. The expression of HER4 was correlated with TNM stage and lymph node metastasis (P<0.01), but not correlated with histological grade (P>0.05). The expression of MMP-9 correlated with T stage, invasion depth, TNM stage, and lymph node metastasis (P<0.05). Conclusion:The expression of HER4 is apparently different in esophageal carcinoma tissues, paracancerous tissues, and normal tissues. Its positive expression in esophageal carcinoma tissues is correlated with TNM stage and lymph node metastasis. The expression of MMP-9 in esophageal carcinoma tissues is correlated with the T stage, TNM staging, and lymph node metastasis. The positive expression of HER4 in esophageal carcinoma tissues is associated with the expressions of MMP-9.
7.Expression of imprinted tumor suppressor gene SLC22A18 in breast eancer
Hongmei XU ; Hoagwei ZHANG ; Yingyong HOU ; Ziqin ZHAO
Chinese Journal of General Surgery 2008;23(5):384-387
Objective To investigate the expression of sLc22A1 8,an impfinted tumor suppressor gene,in breast cancer and explore the relationship between expression of SLC22A18 and the pathogenesis of breast cancer. Methods Real-time quantitative reverse transcriptase-polymerase chain reaction was applied on 46 cases of infiltrating duetal breast carcinoma(IDC),46 csges of corresponding adjacent noncancerous tissues and 20 benign breast tissues in order to detect mRNA expression of SLC22A18 gene.Protein expression was detected by immunohistochemistry.Statistical analysis was carried out to analyse the correlation between SLC22A18 gene expression and various elinical parameters in these breast cancer patients. Results SLC22A18 mRNA expression in 46 IDC tissues Was lower than that in all corresponding adjacent non-cancerous tissues(Z=-4.900,P<0.01).SLC22A18 mRNA expression was lower in breast cancer eases,when compared with that in benign cases(Z=-3.182,P<0.01).SLIC22A18 mRNA expression in 40 IDCs Was lower than that in 6 dutal carcinoma in situ(part of IDC)(Z=-2.022,P<0.05).There was a decreased or completely diminished SLC22A18 protein expression in breast cancer.A significant difference of SLC22A18 protein expression was also observed in IDC and benign groups(P<0.05).Neither mRNA nor protein expression of SLC22A18 gene correlated with clinieopathologic parameters such as age of patients,size of tumor,ehnical stage,pathologic subtype,histologlc grade or lymph node metastasis(P>0.05).Condusion Decreased expression of SLC22A18 gene may play an important role in the carcinogenesis of IDC.
8.Spindle cell carcinoma of the breast:a clinicopathologic analysis of three cases
Zhongyan GUAN ; Yufang FENG ; Zhenkang GAN ; Liang SHI ; Yingyong HOU
Chinese Journal of Clinical and Experimental Pathology 2015;(9):996-1000
Purpose To analyze the clinical pathological characteristics and pathological diagnosis and prognosis of spindle cell carci-noma of the breast. Methods Three cases of spindle cell carcinoma of the breast were studied by morphological and immunohisto-chemical EnVision techniques. Results The females were 48, 63 and 71 years old. The tumors located in the right breast with 4. 0 cm × 3. 0 cm × 3. 0 cm, 3. 0 cm × 2. 0 cm × 2. 0 cm and 3. 5 cm × 2. 8 cm × 2. 3 cm in size and showed cystic lesion. The neoplasm was composed of bland spindle cells and mimicking fibromatosis. Immunohistochemical staining showed that spindle cells were positive for CK(AE1/AE3), CK(34βE12), CK14, CK5/6, p63 and vimentin, negative for ER, PR and c-erbB-2. Ki-67 was positive in 20%, 25% and 20% of the cells. Conclusion Spindle cell carcinoma of the breast is a rare subtype of the metaplastic carcinoma which tend to show cystic changes. It is important to make a definite diagnosis which combine histopathologic features and immunophe-notyping.
9.Methylation and mRNA expression of imprinted gene SLC22A18/TSSC5/BWR1A in breast cancer
Hongmei XU ; Hongwei ZHANG ; Huangyu HE ; Yingyong HOU ; Ziqin ZHAO
Chinese Journal of Pathophysiology 1989;0(05):-
AIM:To study the mRNA expression and methylation status of imprinted gene SLC22A18 in infiltrating ductal carcinomas(IDCs),and the correlation between methylation status and clinical characteristics in IDCs.METHODS:The methylation status at the promoter regions of SLC22A18 gene was examined by methylation-specific polymerase chain reaction(MSP)in the specimens of IDC from 40 patients.The mRNA expression of SLC22A18 gene was detected by real-time reverse quantitative transcriptase polymerase chain reaction(real-time RT-PCR)in 40 specimens of IDC and the cell line MDA-MB-231.The cell line MDA-MB-231 was treated with 5-aza-2'-deoxycytidine(5'-aza-dc)and trichostatin A(TSA),then MSP and rea1-time RT-PCR were used to detect the methylation status and mRNA expression levels of SLC22A18 gene.RESULTS:SLC22A18 mRNA expression in 40 IDC tissues was lower than that in al1 corresponding adjacent non-cancerous tissues(P
10.Dianosis and treatment of hepatic metastasis from gastrointestinal stromal tumor
Yinghao SHEN ; Jia FAN ; Zhiquan WU ; Jian ZHOU ; Shuangjian QIU ; Yingyong HOU ; Yao YU ; Xiaowu HUANG
Chinese Journal of Digestive Surgery 2008;7(6):450-451
Objective To investigate the diagnosis and treatment of hepatic metastasis from gastrointestinal stromal turnor(GIST).Methods The clinical data of 16 patients with GIST who had been admitted to our hospitalfrom December 1993 to May 2007 were retrospectively analyzed.Results Of all patients,14 underwent radical resection and 2 underwent palliative operation.Two patients with palliative operation and 3 with radical resection were administered with imatinib postoperatively. All patients were followed up for 3-161 months,and GIST metastasis and invasion was observed in 8 of the 14 patients who received radical resection.Of the 7 patients with hepatic metastasis.3 were treated with hepatic artery chemoembolization,1 was administered with imatinib,2 received reoperation and 1 did not receive any treatment. Reoperation was carried out on 1 patient who had abdominal wall metastasis.The 1-and 3-year survival rates of the 16 patients were 92%and 74%,respectively.Conclusions The recurrence rate of GIST after hepatectomy is high.Complete surgical resection is the best curative treatment for hepatic metastasis from GIST and GIST recurrence.The combination of surgical resection and imatinib administration may help to improve the prognosis of patients with hepatic metastasis from GIST.